Literature DB >> 27535224

The Breast Cancer Tumor Suppressor TRIM29 Is Expressed via ATM-dependent Signaling in Response to Hypoxia.

Muzaffer Dükel1, W Scott Streitfeld2, Tsz Ching Chloe Tang2, Lindsey R F Backman1, Lingbao Ai1, W Stratford May2, Kevin D Brown3.   

Abstract

Reduced ATM function has been linked to breast cancer risk, and the TRIM29 protein is an emerging breast cancer tumor suppressor. Here we show that, in cultured breast tumor and non-tumorigenic mammary epithelial cells, TRIM29 is up-regulated in response to hypoxic stress but not DNA damage. Hypoxia-induced up-regulation of TRIM29 is dependent upon ATM and HIF1α and occurs through increased transcription of the TRIM29 gene. Basal expression of TRIM29 is also down-regulated in cells expressing diminished levels of ATM, and findings suggest that this occurs through basal NF-κB activity as knockdown of the NF-κB subunit RelA suppresses TRIM29 abundance. We have previously shown that the activity of the TWIST1 oncogene is antagonized by TRIM29 and now show that TRIM29 is necessary to block the up-regulation of TWIST1 that occurs in response to hypoxic stress. This study establishes TRIM29 as a hypoxia-induced tumor suppressor gene and provides a novel molecular mechanism for ATM-dependent breast cancer suppression.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  breast cancer; cell signaling; hypoxia; hypoxia-inducible factor (HIF); tumor suppressor gene

Mesh:

Substances:

Year:  2016        PMID: 27535224      PMCID: PMC5076825          DOI: 10.1074/jbc.M116.730960

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  73 in total

1.  mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α.

Authors:  Hakan Cam; John B Easton; Anthony High; Peter J Houghton
Journal:  Mol Cell       Date:  2010-11-24       Impact factor: 17.970

2.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

3.  Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1.

Authors:  Huasheng Lu; Clifton L Dalgard; Ahmed Mohyeldin; Thomas McFate; A Sasha Tait; Ajay Verma
Journal:  J Biol Chem       Date:  2005-10-13       Impact factor: 5.157

4.  Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma.

Authors:  Y Xu; T Ashley; E E Brainerd; R T Bronson; M S Meyn; D Baltimore
Journal:  Genes Dev       Date:  1996-10-01       Impact factor: 11.361

5.  Absence of linkage to the ataxia telangiectasia locus in familial breast cancer.

Authors:  R Wooster; D Ford; J Mangion; B A Ponder; J Peto; D F Easton; M R Stratton
Journal:  Hum Genet       Date:  1993-08       Impact factor: 4.132

6.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1.

Authors:  Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner
Journal:  Nat Med       Date:  2004-07-04       Impact factor: 53.440

Review 7.  Leukemia and lymphoma in ataxia telangiectasia.

Authors:  A M Taylor; J A Metcalfe; J Thick; Y F Mak
Journal:  Blood       Date:  1996-01-15       Impact factor: 22.113

8.  JunD reduces tumor angiogenesis by protecting cells from oxidative stress.

Authors:  Damien Gerald; Edurne Berra; Yves M Frapart; Denise A Chan; Amato J Giaccia; Daniel Mansuy; Jacques Pouysségur; Moshe Yaniv; Fatima Mechta-Grigoriou
Journal:  Cell       Date:  2004-09-17       Impact factor: 41.582

9.  Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization.

Authors:  Lidong Wang; David G Heidt; Cheong J Lee; Huibin Yang; Craig D Logsdon; Lizhi Zhang; Eric R Fearon; Mats Ljungman; Diane M Simeone
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

10.  Breast and other cancers in families with ataxia-telangiectasia.

Authors:  M Swift; P J Reitnauer; D Morrell; C L Chase
Journal:  N Engl J Med       Date:  1987-05-21       Impact factor: 91.245

View more
  8 in total

1.  iTRAQ-based quantitative proteomic analysis of differentially expressed proteins in chemoresistant nasopharyngeal carcinoma.

Authors:  Kun Wang; Zhen Chen; Lu Long; Ya Tao; Qiong Wu; Manlin Xiang; Yunlai Liang; Xulin Xie; Yuan Jiang; Zhiqiang Xiao; Yahui Yan; Shiyang Qiu; Bin Yi
Journal:  Cancer Biol Ther       Date:  2018-08-01       Impact factor: 4.742

2.  LncRNA HOXA11-AS accumulation-induced microRNA-761 downregulation regulates cell growth by targeting TRIM29 in papillary thyroid cancer.

Authors:  Xiangdang Yin; Jian Zhang; Chaojun Li; Zhe Zhang; Tong Jin; Liyou Song; Rui Zhang; Wei Wang; Youmao Tao; Xiaochun Wang
Journal:  Am J Transl Res       Date:  2019-11-15       Impact factor: 4.060

3.  Clinical significance of TRIM29 expression in patients with gastric cancer.

Authors:  Javad Farhadi; Jamshid Mehrzad; Hassan Mehrad-Majd; Alireza Motavalizadehkakhky
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2022

4.  Loss of TRIM29 suppresses cancer stem cell-like characteristics of PDACs via accelerating ISG15 degradation.

Authors:  Jia Sun; Jing Yan; Huai-Yu Qiao; Fu-Ying Zhao; Chao Li; Jing-Yi Jiang; Bao-Qin Liu; Xiao-Na Meng; Hua-Qin Wang
Journal:  Oncogene       Date:  2019-09-09       Impact factor: 9.867

5.  TRIM14 Promotes Breast Cancer Cell Proliferation by Inhibiting Apoptosis.

Authors:  Gaowu Hu; Wei Pen; Ming Wang
Journal:  Oncol Res       Date:  2018-03-21       Impact factor: 5.574

Review 6.  TRIM29 in Cutaneous Squamous Cell Carcinoma.

Authors:  Che-Yuan Hsu; Teruki Yanagi; Hideyuki Ujiie
Journal:  Front Med (Lausanne)       Date:  2021-12-20

7.  ATDC mediates a TP63-regulated basal cancer invasive program.

Authors:  Phillip L Palmbos; Yin Wang; Armand Bankhead Iii; Alan J Kelleher; Lidong Wang; Huibin Yang; McKenzie L Ahmet; Erica R Gumkowski; Samuel D Welling; Brian Magnuson; Jacob Leflein; Guadalupe Lorenzatti Hiles; Ethan V Abel; Michele L Dziubinski; Sumithra Urs; Mark L Day; Mats E Ljungman; Diane M Simeone
Journal:  Oncogene       Date:  2019-01-14       Impact factor: 9.867

8.  EDN1-AS, A Novel Long Non-coding RNA Regulating Endothelin-1 in Human Proximal Tubule Cells.

Authors:  Lauren G Douma; Kristen Solocinski; Sarah H Masten; Dominique H Barral; Sarah J Barilovits; Lauren A Jeffers; Kareme D Alder; Ravi Patel; Charles S Wingo; Kevin D Brown; Brian D Cain; Michelle L Gumz
Journal:  Front Physiol       Date:  2020-03-13       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.